Included patients (n = 91) | |
---|---|
Age, years* | 67 (24–88) |
Male sex, n (%) | 66 (72.5) |
APACHE II* | 11 (2–28) |
Co-morbidities, n (%): | |
Malignancy | 14 (15.4) |
Cardiovascular | 26 (28.6) |
Pulmonary | 33 (36.3) |
Diabetes Mellitus | 21 (23.1) |
Urogenitala | 14 (15.4) |
Hepatic | 8 (8.8) |
Haematologicalb | 12 (13.2) |
Neurologicalc | 18 (19.2) |
Charlson score* | 4 (0–10) |
McCabe score** | 1.48 ± 0.64 |
Patients with CKD1 at baseline | 19 (20.9) |
Type of infection, n (%): | |
Pneumonia | 24 (24.6) |
Urinary tract infection | 22 (24.2) |
Skin and soft tissue infection | 11 (12.1) |
Organ space surgical site infection | 10 (11) |
Bacteremia | 6 (6.6) |
Other | 18 (19.8) |
Hospital-acquired infection, n (%) | 86 (94.5) |
Department of hospitalization: | |
Medical | 44 (48.2) |
Surgical | 32 (35.2) |
ICU2 | 15 (16.2) |
Admission diagnosis category: | |
Infection | 26 (28.6) |
Other-medical | 35 (38.5) |
Other-surgical | 30 (33) |
CMS3 daily dose (millions of IU4)** | 5.45 ± 2.21 |
CMS3 total dose (millions of IU4)** | 108.36 ± 96.41 |
CMS3 duration of treatment, days** | 20.18 ± 16.01 |
Inhaled CMS3, n (%) | 14 (15.4) |
Combined antimicrobial therapy, n (%) | 46 (50.5) |
Css 5 (mg/L)** | 1.67 ± 1.42 |
Css 5 > 1.28 (mg/L), n (%) | 46 (50.5) |
Css 5/MIC6** | 3.43 ± 2.91 |
AKI7 prior to CMS3 treatment, n (%) | 12 (13.2) |
Patients with AKI at day 7, n (%) | |
R (Risk) | 19 (20.9) |
I (Injury) | 9 (9.9) |
F (Failure) | 2 (2.2) |
Patients with AKI7 at the EOT8, n (%) | |
R (Risk) | 12 (13.2) |
I (Injury) | 27 (27.7) |
F (Failure) | 10 (11) |
Clinical response, n (%) | 72 (79.1) |
30-Day all-cause mortality, n (%) | 28 (30) |
Hospital length-of-stay (days)* | 67 ± 53.97 |